Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth W Mahaffey

Showing results (551-560 of 577) with videos related to

Pageof 58
Sort By:
Journal of the American College of Cardiology|November 15, 2018
Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES TrialMichael Szarek, Harvey D White, Gregory G Schwartz, et al.
Journal of the American College of Cardiology|November 12, 2013
Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome)David J Whellan, Pierluigi Tricoci, Edmond Chen, et al.
Journal of the American College of Cardiology|September 4, 2024
ApoA-I Infusions and Burden of Ischemic Events After Acute Myocardial Infarction: Insights From the AEGIS-II TrialC Michael Gibson, Gerald Chi, Danielle Duffy, et al.
American Heart Journal|August 30, 2024
Milvexian vs apixaban for stroke prevention in atrial fibrillation: The LIBREXIA atrial fibrillation trial rationale and designSneha S Jain, Kenneth W Mahaffey, Karen S Pieper, et al.
Circulation|December 28, 2018
Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 TrialsAlexander C Fanaroff, Robert Clare, Karen S Pieper, et al.
Journal of Thrombosis and Thrombolysis|March 16, 2013
Highlights from the fifth international symposium of thrombosis and anticoagulation (ISTA V), October 18-19, 2012, Belo Horizonte, Minas Gerais, BrazilRenato D Lopes, Richard C Becker, L Kristin Newby, et al.
The American Journal of Medicine|April 30, 2016
North American Thrombosis Forum, AF Action Initiative Consensus DocumentChristian T Ruff, Jack E Ansell, Richard C Becker, et al.
American Heart Journal|August 2, 2017
Use of troponin assay 99th percentile as the decision level for myocardial infarction diagnosisAkshay Bagai, Karen P Alexander, Jeffrey S Berger, et al.
Journal of the American Heart Association|November 7, 2022
Randomized Clinical Trial to Evaluate an Atrial Fibrillation Stroke Prevention Shared Decision-Making PathwayPaul J Wang, Ying Lu, Kenneth W Mahaffey, et al.
European Heart Journal|September 2, 2024
Apolipoprotein A-I infusions and cardiovascular outcomes in acute myocardial infarction according to baseline LDL-cholesterol levels: the AEGIS-II trialC Michael Gibson, Danielle Duffy, Maria Cecilia Bahit, et al.
Pageof 58

Showing results (551-560 of 577) with videos related to

Sort By:
Pageof 58
Journal of the American College of Cardiology|November 15, 2018
Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES TrialMichael Szarek, Harvey D White, Gregory G Schwartz, et al.
Journal of the American College of Cardiology|November 12, 2013
Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome)David J Whellan, Pierluigi Tricoci, Edmond Chen, et al.
Journal of the American College of Cardiology|September 4, 2024
ApoA-I Infusions and Burden of Ischemic Events After Acute Myocardial Infarction: Insights From the AEGIS-II TrialC Michael Gibson, Gerald Chi, Danielle Duffy, et al.
American Heart Journal|August 30, 2024
Milvexian vs apixaban for stroke prevention in atrial fibrillation: The LIBREXIA atrial fibrillation trial rationale and designSneha S Jain, Kenneth W Mahaffey, Karen S Pieper, et al.
Circulation|December 28, 2018
Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 TrialsAlexander C Fanaroff, Robert Clare, Karen S Pieper, et al.
Journal of Thrombosis and Thrombolysis|March 16, 2013
Highlights from the fifth international symposium of thrombosis and anticoagulation (ISTA V), October 18-19, 2012, Belo Horizonte, Minas Gerais, BrazilRenato D Lopes, Richard C Becker, L Kristin Newby, et al.
The American Journal of Medicine|April 30, 2016
North American Thrombosis Forum, AF Action Initiative Consensus DocumentChristian T Ruff, Jack E Ansell, Richard C Becker, et al.
American Heart Journal|August 2, 2017
Use of troponin assay 99th percentile as the decision level for myocardial infarction diagnosisAkshay Bagai, Karen P Alexander, Jeffrey S Berger, et al.
Journal of the American Heart Association|November 7, 2022
Randomized Clinical Trial to Evaluate an Atrial Fibrillation Stroke Prevention Shared Decision-Making PathwayPaul J Wang, Ying Lu, Kenneth W Mahaffey, et al.
European Heart Journal|September 2, 2024
Apolipoprotein A-I infusions and cardiovascular outcomes in acute myocardial infarction according to baseline LDL-cholesterol levels: the AEGIS-II trialC Michael Gibson, Danielle Duffy, Maria Cecilia Bahit, et al.
Pageof 58